-
Company Insights
![]()
DHL Group – Digital Transformation Strategies
DHL Group Digital Transformation Strategies Report Overview DHL Group (DHL) is strengthening its focus on the use of innovative technologies to enhance its operational efficiency. Cloud, AI, blockchain, robotics, and big data are among the technologies the company is focusing on. The annual ICT spending of DHL is estimated at $2.5 billion for 2023. A major share of this spending is earmarked for software, hardware, and network and communications. DHL is a global logistics company operating under two brands, namely...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Primary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Primary CNS Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a CD19-directed genetically...
-
Company Insights
New![]()
Top Logistics Foreign Direct Investment Companies
Top Logistics Foreign Direct Investment Companies report analyzes the most active greenfield FDI investors globally (based on number of projects) in the Logistics sector between Q1 2019 and Q3 2023. Additionally, the report highlights where these top Logistics investors are investing in what type of operations. The report also provides an overview of notable FDI projects from these top investors. The report will be delivered within 2-3 business days of the purchase, excluding weekends and holidays. Certain sections of the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Nodal Marginal Zone B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Nodal Marginal Zone B-Cell Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) Drug Details:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Splenic Marginal Zone B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Splenic Marginal Zone B-Cell Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia (CLL) Drug Details: Lisocabtagene maraleucel (Breyanzi) is a CD19-directed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Secondary CNS Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a CD19-directed genetically...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Relapsed Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details: Lisocabtagene maraleucel (Breyanzi) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Mantle Cell Lymphoma Drug Details: Lisocabtagene maraleucel (Breyanzi) is a CD19-directed genetically...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.